Scientific Program

Conference Agenda

Day 1

FRIDAY - 4TH SEPTEMBER

07:30 – 08:00

Registration

08:00 – 08:15

Conference Opening

Dr. Amal Alabdulwahab 🇸🇦

SESSION I

MYELOID MALIGNANCY | MAIN HALL

Dr. Ahmad Alsaeed

08:15 – 08:35

Fitness Assessment in AML Guidelines

Dr. Ihab El Hemaidi 🇸🇦

08:35 – 08:55

Pre-MDS: CHIP / CCUS / ICUS

Dr. Sayed Osman 🇸🇦

08:55 – 09:15

Biological therapy in AML: current strategies and future direction

Prof. Naval Daver 🇺🇸

09:15 – 09:25

Q&A Discussion

09:25 – 09:40

Coffee break.

SESSION 2

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | MAIN HALL

Dr. Samir Al Amoudi

09:40 – 10:00

Uncommon forms of ALL

Dr. Mohammed Bakkar 🇸🇦

10:00 – 10:20

CAR T-Cell Therapy: a consolidation approach or a bridge to allogeneic stem transplantation

Prof. John Gribben 🇬🇧

10:20 – 10:50

Allogeneic HSCT for adults with ALL: Rationale, recent trials and current practice

Prof. David Marks 🇬🇧

10:50 – 11:10

Q&From Clinical Evidence to Local Practice

Dr. Ahmed Absi 🇸🇦

11:10 – 11:25

Q&A

12:30 – 14:00

Lunch and Prayer

Meet the expert Session | Al Diwaniya Hall

TBA

11:00 – 11:45

Meet the Expert: Histiocytosis

Dr. Hind Salama 🇸🇦

11:45 – 12:00

SERB Satellite Symposium

TBA

SESSION 3

Moderator

Dr. Ghazi Alotaibi

Dr.Binyan

13:00 – 13:20

Chemotherapy-free approaches in MCL

Prof. Pier Luigi Zinzani 🇮🇹

13:20 – 13:40

T-cell lymphoma: current challenges and emerging therapies

Prof. Pier Luigi Zinzani 🇮🇹

13:40 – 14:00

CAR T-Cell Therapy and bispecifics in LBCL: does sequencing matter

Dr. Marco Ruella 🇺🇸

Roche Satellite Symposium | Main Hall

Dr. Alhassan Bajawi

14:00 – 14:20

Charting the Changing Currents in Second-Line DLBCL Treatments

Saleem Eldadah

14:20 – 14:30

Q&A

14:30 – 15:00

Coffee Break & Asr prayer

SESSION 4

EMERGING ISSUES IN PRACTICE | MAIN HALL

Dr. Khalofa Alghamdi

15:00 – 15:20

Tailoring SCD Treatment

Dr. Mohsen Alzahrani 🇸🇦

15:20 – 15:40

Haemophilia: Beyond Factor Support

Dr. Ashraf Warsi 🇸🇦

15:40 – 16:00

Evidence-based transfusion support in malignant hematology

Dr. Maha Badawi 🇸🇦

16:00 – 16:15

Asciminib reshaping CML management in frontlines

16:20 – 16:30

Satellite Symposium

Dr. Abdullah Alamer

16:30-16:45

Q&A

Day 2

SATURDAY - 5TH SEPTEMBER

SESSION I

M U LT I P L E M Y E LO M A ( M M ) | MAIN HALL

Majed Alahmadi

Dr. Abdullah Alamer

08:30 – 08:50

MM new response and risk criteria

Dr. Omar Abduljalil 🇸🇦

08:50 – 09:10

The pillars of myeloma care beyond myeloma therapy

Dr. Enas Mutahar 🇸🇦

09:10 – 09:30

Resistance to immune therapy in myeloma: mechanism and impact on sequencing of treatment

Dr. Evangelos Terpos 🇬🇷

09:30 – 09:50

CAR-T / bispecific antibodies update

Dr. Evangelos Terpos 🇬🇷

09:50 – 10:05

Role and sequencing of BCMA agent in RR MM

Majed Alahmadi

10:05 – 10:20

Q&A

10:20 – 10:35

Coffee Break

SESSION 2

CHRONIC LEUKEMIA | MAIN HALL

Mohamed Atiah

Dr. Amjad Althobaiti

10:35 – 10:55

Individualized treatment selection in MF

Dr. Omar Albanyan 🇸🇦

10:55 – 11:15

CML management in 2026 / precision decision-making in malignant hematology

Dr. Timothy Hughes 🇦🇺

11:15 – 11:35

Chasing Zero: The Evolving Landscape of MRD testing in AML

Dr. Yehya Alghamdi 🇸🇦

11:35 – 11:50

Refining clinical practice for MF patient with anemia

11:50 – 12:05

Q&A

12:05 – 12:55

Prayer and Lunch

SESSION 3

LYMPHOMA | MAIN HALL

Dr. Alhassan Bajawi

Dr. Manal Alsagaf

12:55-13:15

Evolving landscape in frontline management of HL

Dr. Alfadal Alshaibani 🇸🇦

13:30 – 14:00

Debate: Low Intensity Therapy in Younger Fit AML Patients – CON

13:15-13:35

Unusual forms of NHL

Abdulwahab Babtain

13:35 - 13:55

CLL management post-BTK failure

Dr. Ahmed Absi 🇸🇦

13:55-14:10

Latest updates of Zanubrutinib in the management of CLL

Mohamed Atiah

14:10-14:25

Q&A

SESSION 4

DEBATE | MAIN HALL

Dr. Eman Alhazmi

Dr. Ahmed Barefah

14:25-14:40

Low-intensity therapy in younger fit AML patients: YES

Dr. Naif Aljuhani 🇸🇦

14:40-14:55

Low-intensity therapy in younger fit AML patients: NO

Dr. Salem bahashwan 🇸🇦

14:55-15:10

Chemotherapy-free regimens in frontline ALL Ph positive: YES

Dr. Hanan Alkhaldi 🇸🇦

15:10-15:25

Chemotherapy-free regimens in frontline ALL Ph positive: NO

Dr. Sakher Alotaibi 🇸🇦

15:35-15:50

MDS Patient Cases: Challenges, Decisions, and Outcomes

Bassim Albeirouti

15:50-16:10

Satellite Symposium

Saleem Eldadah

16:10-16:25

Q&A

16:25-16:30